MarketPulse

enrollment violations

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Nektar Therapeutics Faces Securities Fraud Suit Over Clinical Trial Protocol Violations

Nektar Therapeutics faces securities class action lawsuit alleging REZOLVE-AA trial enrolled four ineligible patients, masking disappointing efficacy results.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Nektar Therapeutics Faces Class Action Over REZOLVE-AA Trial Disclosure Failures

Class action lawsuit filed against $NKTR for allegedly concealing REZOLVE-AA trial protocol violations and ineligible patient enrollment. Stock fell 7.77% on trial failure announcement.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Nektar Therapeutics Faces Securities Fraud Class Action Over Failed Clinical Trial

Pomerantz LLP filed class action against $NKTR over REZOLVE-AA trial failure. Stock dropped 7.77% after December disclosure of ineligible patient enrollment issues.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Nektar Therapeutics Faces Class Action Over Failed Trial Enrollment Claims

Pomerantz LLP sues Nektar Therapeutics for alleged securities fraud over failed clinical trial enrollment; stock falls 7.77%.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.
NKTRsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Nektar Therapeutics Faces Class Action Over Failed Trial and Alleged Disclosure Failures

Nektar Therapeutics faces class action lawsuit over alleged failure to disclose enrollment protocol violations in failed Phase 2b REZOLVE-AA trial, triggering 8% stock decline.
NKTRclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosure

Nektar Therapeutics faces securities class action over alleged misstatements about REZOLVE-AA trial, with stock falling 7.77% after trial failure announcement.
NKTRclass actionstock price decline